Sugi Predict

Sugi Predict / Compounds / SCHEMBL7189845

SCHEMBL7189845

SCHEMBL7189845

Cc1cc(C)c(C(=O)P(=O)(C(=O)c2c(C(C)(C)C)cc(C(C)(C)C)cc2C(C)(C)C)c2ccccc2)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ALOX5 P09917 2/20 0.36
▸ PTGS2 P35354 2/20 0.36
▸ RXRB P28702 2/20 0.35
▸ RXRA P19793 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ STAT5B P51692 1/20 0.34
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ KCNK9 Q9NPC2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183900 0.96 MEN1 (0.39) LMNAMEN1GAAKMT2AALOX5
SCHEMBL7180182 0.93 LMNA (0.40) LMNAMEN1GAAKMT2ARXRB
SCHEMBL7181473 0.91 NPSR1 (0.39) LMNAMEN1GAAKMT2AALOX5
SCHEMBL17403668 0.91 LMNA (0.39) LMNAMEN1GAAKMT2ANPSR1
SCHEMBL19845116 0.89 LMNA (0.40) LMNAMEN1GAAKMT2ANPSR1
SCHEMBL7187514 0.89 LMNA (0.40) LMNAMEN1GAAKMT2ARXRB
SCHEMBL7189042 0.88 MEN1 (0.35) LMNAMEN1GAAKMT2AALOX5
SCHEMBL7182360 0.85 TP53 (0.39) LMNAMEN1GAAKMT2ARXRB
SCHEMBL15158 0.85 LMNA (0.40) LMNAMEN1KMT2AHTTSMN1; SMN2
SCHEMBL7179675 0.84 LMNA (0.37) LMNAMEN1GAAKMT2ARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885MEN1 2312/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885MEN1 2263/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.